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Patients with insulin resistance and early type 2 diabetes exhibit an increased propensity to develop a diﬀuse and extensive pattern
of arteriosclerosis. Typically, these patients show increased levels of C-peptide and over the last years various groups examined the
eﬀect of C-peptide in vascular cells as well as its potential role in lesion development. While some studies demonstrated beneﬁcial
eﬀects of C-peptide, for example, by showing an inhibition of smooth muscle cell proliferation, others suggested proatherogenic
mechanisms in patients with type 2 diabetes. Among them, C-peptide may facilitate the recruitment of inﬂammatory cells into
early lesions and promote lesion progression by inducing smooth muscle cell proliferation. The following review will summarize
theeﬀectsofC-peptideinvascularcellsanddiscussthepotentialroleofC-peptideinatherogenesisinpatientswithtype2diabetes.
Copyright © 2008 N. Marx and D. Walcher. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Patients with diabetes and insulin resistance exhibit an in-
creased propensity to develop arteriosclerosis with its se-
quelae acute myocardial infarction and stroke [1]. Due
to peripheral insulin resistance, these patients temporarily
demonstrate elevated levels of the proinsulin cleavage prod-
uct C-peptide. For a long time, C-peptide has been con-
sidered to be biological inert until recent work in kidney
cells suggest that C-peptide can activate intracellular signal-
ing pathways such as NA-K-ATPase [2, 3]. In addition, ex-
perimental data have shown activation of MAP kinase in ﬁ-
broblasts and lung endothelial cells as well as activation of
protein kinase C and PI3-kinase through C-peptide [4, 5].
These data suggested that C-peptide may be biologically ac-
tive. Moreover, various groups demonstrated that C-peptide
administration inpatientswithtype1diabetes mellitusame-
liorates diabetes-induced renal and nerve dysfunction [6, 7].
Wallerath et al. demonstrated that C-peptide stimulates the
release of NO in endothelial cells in vitro and that this ef-
fect is mediated by an induction of Ca2+ inﬂux into the cells
[8]. Such mechanism may also explain some of the beneﬁcial
eﬀects of C-peptide in type 1 diabetes.
In addition, recent work addressed eﬀects of C-peptide
in vascular cells; the following review will focus on these ef-
fects and discuss the potential relevance for atherogenesis in
patients with type 2 diabetes.
2. ATHEROGENESIS
According to our current understanding, atherogenesis is an
i n ﬂ a m m a t o r yp r o c e s si nt h ev e s s e lw a l lw i t hd i ﬀerent phases
and stages [9]. The early phase, before any appearance of
microscopic or macroscopic changes, is characterized by en-
dothelial dysfunction. Under the inﬂuence of cardiovascular
riskfactors,theendotheliumloosesitsintegrityandbecomes
permeable for plasma compounds like low-density lipopro-
tein (LDL) which can enter the vessel wall and deposit in the
subendothelial space. In addition, during endothelial dys-
functiontheendotheliumreleasescytokinesandchemotactic
proteins and expresses adhesion molecules on the cell sur-
face. Such mechanisms facilitate the recruitment of mono-
cytes and CD4+ lymphocytes, important inﬂammatory cells
during lesion development [10]. Once these cells have en-
tered the vessel wall, monocytes diﬀerentiate to macrophages
and express scavenger receptors on their surface to promote2 Experimental Diabetes Research
the uptake of oxidized LDL. These lipid-loaden cells then
become foam cells, the classical cellular substrate of fatty-
streaks. Foam cells release various kinds of proinﬂamma-
tory and prothrombotic mediators and play a critical role in
plaque progression. CD4+ lymphocytes are also attracted by
chemokines and enter the vessel wall as na¨ ıve TH0 cells. In
the subendothelial space, these cells then encounter antigens
like oxidized LDL and diﬀerentiate towards TH1 cells which
release proinﬂammatory cytokines such as IFNγ,T N F α,a n d
IL-2. Some of these cytokines then enhance endothelial ex-
pression and release of T-cell speciﬁc chemokines, creating
a vicious cycle of cell activation and cell recruitment [11]. In
addition,theseTH1cytokinesactivateothercellsinthevessel
wall like macrophages and smooth muscle cells (SMCs), thus
orchestrating the inﬂammatory response in the vessel wall.
With increased recruitment of these inﬂammatory cells fatty
streaks develop and SMCs from the media start to proliferate
and migrate into the intima. As lesion formation progresses,
advanced and potentially complicated lesions are formed.
These lesions may lead to a progressive narrowing of the ves-
sel wall thus potentially creating stable angina if located in
the coronary artery. Alternatively, these plaques may become
vulnerable and upon rupture can cause an acute coronary
syndrome [12].
3. C-PEPTIDE DEPOSITION IN EARLY
ARTERIOSCLEROTIC LESIONS
Since endothelial dysfunction with increased permeability
occurs in patients with insulin resistance and early type
2 diabetes, a group of patients with temporarily high C-
peptide serum levels, it has been hypothesized that C-
peptide might deposit in the vessel wall in these patients in
early atherogenesis. Immunohistochemical analyses of early
arteriosclerotic lesions of patients with diabetes from the
PDAY study (pathobiological determinants of atheroscle-
rosis in youth) revealed C-peptide deposition mainly in
the subendothelial space and the intima. Some of the di-
abetic subjects also exhibited C-peptide deposition in the
media. In contrast, only very little C-peptide deposition
has been found in early arteriosclerotic lesions of nondia-
betic subjects. Computer-assisted analyses revealed signiﬁ-
cantly higher C-peptide deposition in lesions from diabetic
individuals compared to lesions of age, sex, and risk fac-
tor matched nondiabetic subjects [13]. Interestingly, no de-
position of insulin or proinsulin was detectable in diabetic
or nondiabetic subjects. Staining of parallel sections as well
as immunoﬂuorescence techniques demonstrated colocal-
isation of C-peptide with intimal monocyte/macrophages
and CD4+ lymphocytes in some of the diabetic individuals
[14]. In the studies cited above, C-peptide deposition has
been found in 100% of the 21 diabetic individuals exam-
ined, while monocyte inﬁltration was only present in 77%,
and CD4+ lymphocyte inﬁltration only in 57%. These data
suggested that C-peptide deposition may precede mono-
cyte and T-cell migration into the vessel wall. Based on
this observation, the hypothesis was raised that C-peptide
may deposit in the vessel wall during early atherogenesis
and then—through chemotactic eﬀects—promote the re-
c r u i t m e n to fm o n o c y t e sa n dC D 4 + lymphocytes. Still, it re-
mains unclear to what extent other peptides may also de-
posit in the subendothelial space and exhibit similar ef-
fects.
4. CHEMOTACTIC ACTIVITY OF C-PEPTIDE TOWARDS
MONOCYTES AND CD4+ LYMPHOCYTES
In vitro migration assays, employing a modiﬁed Boyden
chamber, revealed that C-peptide induces the migration of
both monocytes and CD4+ lymphocytes in a concentration-
dependent manner. Interestingly, insulin did not have such
an eﬀect. The chemotactic eﬀects of C-peptide on these cells
were within the range of very well-established chemokines
like MCP-1 and RANTES. In addition, checkerboard analy-
ses showed that C-peptide induces chemotaxis rather than
chemokinesis [13, 14]. Interestingly, C-peptide does not
exhibit any chemotactic activity towards neutrophils, cells
which are not present in arteriosclerotic lesions.
Inhibition migration assays as well as western blot analy-
ses and activity assays demonstrated that C-peptide mediates
its chemotacticactivitythroughanasof yetunidentiﬁed per-
tussis toxin sensitive G-protein coupled receptor with subse-
quent downstream activation of PI3-kinase γ.
In summary, these data suggest that—during endothe-
lial dysfunction with increased endothelial permeability—C-
peptide may deposit in the arterial intima in patients with
insulin resistance and early type 2 diabetes mellitus and sub-
sequently attract monocytes and CD4+ lymphocytes into the
vessel wall (Figure 1). Such mechanisms may promote lesion
development and potentially explain why patients with di-
abetes develop such a diﬀuse and extensive pattern of arte-
riosclerosis at a very early time point.
In addition to these proatherogenic eﬀects, interesting
data in monocyte-like THP1 cells showed that C-peptide in-
creases the expression of CD36, an important scavenger re-
ceptor for the macrophage uptake of oxidized LDL in arte-
riosclerotic lesions [15]. These data suggest that C-peptide—
in addition to its chemotactic eﬀects on monocytes—may
also promote the diﬀerentiation of monocyte/macrophages
towards foam cells, thus representing another potential
proatherogenic eﬀect of C-peptide.
5. C-PEPTIDE AND SMOOTH MUSCLE
CELL PROLIFERATION
Since C-peptide also colocalized with SMCs in the media
of early arteriosclerotic lesions in some diabetic subjects, it
has been suggested that C-peptide could also exhibit biolog-
ical activity in these cells [16]. SMCs play a crucial role in
the development of arteriosclerotic lesions and the forma-
tion of fatty streaks. In addition, SMCs are of critical im-
portance in the formation of restenosis after coronary in-
tervention: after vascular injury these cells start to prolifer-
ate and then migrate into the developing neointima, becom-
ing the major cellular substrate of the restenotic tissue [17].
These mechanisms seem to be accelerated in patients with
diabetes and insulin resistance, thus contributing to their in-
creasedriskofrestenosisaftercoronaryintervention[18,19].N. Marx and D. Walcher 3
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Figure 1: Potential role of C-peptide in early atherogenesis in patients with insulin resistance and early type 2 diabetes mellitus. During
endothelial dysfunction with increased endothelial permeability, C-peptide could deposit in the intima and through its chemotactic activity
on monocytes and CD4+ lymphocytes facilitate the recruitment of these inﬂammatory cells into the vessel wall.
Several mechanisms like the release of growth factors from
activated platelets as well as the secretion of stimulatory
mediators from inﬂammatory cells have been shown to in-
duce SMC proliferation during atherogenesis and resteno-
sis formation [9]. Conﬂicting data exist on the role of C-
peptide in SMC proliferation. A recent report coming from
Kobayashi et al. demonstrated an inhibition of rat SMC pro-
liferation after 3 days of treatment with human C-peptide
under high glucose concentrations [20]. These eﬀects ob-
served at high C-peptide concentrations (100nmol/L) were
mediated by an inhibition of PDGF-beta receptor expres-
sion as well as by a reduction in p42/p44 MAP-kinase phos-
phorylation. These data are in contrast to results from our
own group demonstrating an induction of SMC prolifera-
tion upon C-peptide stimulation [16]. In our experimental
setting, human C-peptide induced the proliferation of hu-
manSMCswhileratC-peptideexhibitedsimilareﬀectsinrat
SMCs. These mitogenic eﬀects of C-peptide on SMCs were
inhibited by a speciﬁc inhibitor of Src-kinase as well as trans-
fection of cells with short interference RNA (siRNA) against
Src. Similarly, inhibition of PI3-kinase and MAP-kinase re-
duced C-peptide-induced SMC proliferation. Moreover, C-
peptide induced Src phosphorylation as well as activation of
PI3-kinase and ERK 1/2, promoting the concept that these
signalling molecules are involved in C-peptide induced SMC
proliferation. Moreover, C-peptide increased cyclin D1 ex-
pression as well as phosphorylation of the retinoblastoma
protein(Rb).ThesedatasuggestthatC-peptideinducesSMC
proliferation and demonstrate another mechanism how C-
peptide may contribute to plaque development and resteno-
sis formation in patients with insulin resistance and early
type 2 diabetes. Diﬀerent experimental conditions may ac-
count for the discrepant results between the two studies cited
and future work is warranted to further elucidate this issue.4 Experimental Diabetes Research
6. C-PEPTIDE AND MICROVASCULAR THROMBUS
FORMATION IN MICE
Interesting experimental data demonstrated a delay of mi-
crovascular thrombus formation in normal and diabetic
mice upon high-dose C-peptide treatment. Such mecha-
nisms were most likely mediated by a reduction in endothe-
lial plasminogen activator inhibitor 1 (PAI-1) expression in
arterioles and venules, but not by an eﬀect on platelet activa-
tion. Interestingly, concomitant treatment with insulin abol-
ished the eﬀectof C-peptide on microvascular thrombus for-
mation [21]. These data suggest that C-peptide could exhibit
antithrombotic actions in vivo.
Additional eﬀects of C-peptide on endothelial function
as well as on endothelial-leukocyte interaction are discussed
by Kunt and Pfutzner in the same issue of this journal.
7. SUMMARY AND FUTURE PROSPECTS
The majority of data described above suggest that C-peptide
may promote lesion development in patients with type 2
diabetes mellitus and insulin resistance, while the applica-
tion of C-peptide in type 1 diabetic patients who lack C-
peptide has been shown to improve diabetic microvascular
complications such as diabetic neuropathy. Is the potential
proatherogenic action of C-peptide in contrast to such clin-
ical beneﬁts of C-peptide treatment in patients with type
1 diabetes?—Deﬁnitely not. When one compares the situa-
tion of C-peptide in type 1 and type 2 diabetic patients with
the clinical presentation of hypo- and hyperthyroidism, C-
peptide’seﬀectsare not contradictory. L-thyroxine treatment
in patients with hypothyroidism is without any doubt bene-
ﬁcial, but elevated levels of L-thyroxine in those with hyper-
thyroidism can cause serious clinical manifestations. Similar
mechanisms may apply for C-peptide: supplementation of
C-peptide in type 1 diabetic patients may be beneﬁcial while
an increase in C-peptide levels in patients with insulin resis-
tance and type 2 diabetes may be harmful.
Further studies in animal models of arteriosclerosis are
warranted to examine whether the hypothesis of C-peptide’s
proatherogenic eﬀects holds true in vivo. Moreover, addi-
tional work is needed to identify the C-peptide receptor.
Such a receptor could be an interesting therapeutical target
for both, patients with type 1 or type 2 diabetes. Activating
suchareceptorcouldbebeneﬁcialintype1diabeticpatients,
whileblockingofC-peptidereceptorsinpatientswithinsulin
resistance and early type 2 diabetes may help to prevent vas-
cular complications from early on.
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